Drug Profile
Recombinant human growth hormone - Changchun Institute of Biological Products
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Changchun Institute of Biological Products
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Somatotropin-deficiency in China (Injection)
- 30 Aug 2016 Preclinical trials in Somatotropin deficiency in China (Injection) before August 2016 (Changchun Institute of Biological Products pipeline, August 2016)